Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study.

Background And Aims: Pirfenidone (PFD), an oral antifibrotic drug, has been authorized by the EMA and FDA for treatment of idiopathic pulmonary fibrosis. Few studies have addressed its use in advanced liver fibrosis (ALF). We evaluated a prolonged-release formulation (PR-PFD) plus standard of care on disease progression in ALF.

[Extrahepatic symptoms of HCV infection].

Numerous extrahepatic manifestations have been reported in association with hepatitis c virus (HCV) infection, including mixed cryoglobulinemia, porphyria cutanea tarda, membranoproliferative glomerulonephritis, and a high prevalence of autoantibodies. The aims of the present paper is to present the prevalence of clinical and biologic extrahepatic manifestation and to identify associations between these manifestation. The prevalence of dermatologic, rheumatologic, neurological, and nephrologic manifestations, diabetes, arterial hypertension, autoantibodies, and cryoglobulins and liver histologic factors associated with the presence of extrahepatic manifestations reported in the literature.